|1.||Peng, Z: 1 article (01/2014)|
|2.||Härkönen, P: 1 article (01/2014)|
|3.||Väänänen, K: 1 article (01/2014)|
|4.||Kangas, L: 1 article (01/2014)|
|5.||Krishnan, Venkatesh: 1 article (03/2008)|
|6.||Jaffe, Robert B: 1 article (03/2008)|
|7.||Draper, Michael W: 1 article (03/2008)|
|8.||Wong, Mayme: 1 article (03/2008)|
|9.||Shelly, Wendy: 1 article (03/2008)|
|10.||Du, Juan: 1 article (12/2005)|
|1.||Breast Neoplasms (Breast Cancer)
01/01/1994 - "A phase II study compared droloxifene in dosages of 20, 40, and 100 mg daily in postmenopausal women with metastatic, or inoperable recurrent, or primary locoregional breast cancer who had not received prior hormonal therapy. "
01/01/1994 - "Phase I trial of droloxifene in patients with metastatic breast cancer."
01/01/1992 - "Droloxifene, a new anti-oestrogen in postmenopausal advanced breast cancer: preliminary results of a double-blind dose-finding phase II trial."
04/01/2003 - "The insensitivity of MCF-7/Adr human breast cancer cells to droloxifene was associated with the loss of ER. "
01/01/1998 - "The effect of droloxifene (3-hydroxytamoxifen) given as first-line endocrine treatment was evaluated in 39 postmenopausal women with advanced receptor-positive or receptor-unknown breast cancer. "
09/15/1994 - "In vivo, Droloxifene displayed increased growth inhibition of different tumors of animal (R3230AC and 13762) and human origin (T61). "
09/15/1994 - "As another consequence of the high stability of the complex formed by Droloxifene binding to the ER, intermittent exposures with clinically relevant concentrations of Droloxifene brought about effective growth inhibition of human ER positive tumor cells even after short-term application. "
09/01/1993 - "The estrogenic and antiestrogenic activities of droloxifene in human breast cancers."
09/14/1992 - "This mechanism may be related to the clinically important antiproliferative action of droloxifene on cancer cells."
09/14/1992 - "This inhibition of lipid peroxidation by droloxifene may result from a membrane stabilization that could be associated in cancer cells with decreased plasma membrane fluidity. "
05/01/2002 - "The hazard ratio (droloxifene/tamoxifen) for the primary endpoint, time to disease progression, was 1.287 favoring tamoxifen (95% C.I.: 1.114-1.487; p <.001). "
05/01/2002 - "This trial was designed to demonstrate equivalence between droloxifene 40 mg/d and tamoxifen 20 mg/d as first-line treatment in pre- and post-menopausal women with ER+ and/or PgR+ advanced breast cancer based on time to disease progression and tumor response. "
|4.||T-Cell Leukemia (Leukemia, T Cell)
08/01/1989 - "Antiestrogenic and antitumor effects of droloxifene in experimental breast carcinoma."
09/15/1994 - "Therefore, it can be assumed that Droloxifene may represent an important step forward in the treatment of mammary carcinomas in women through its better tolerability and increased efficacy compared with Tamoxifen. "
08/01/1989 - "Droloxifene showed about 20-fold and 3-fold higher affinity to estrogen receptors (ER) in the rat uterus and human ER positive MCF-7 breast carcinoma cells, respectively, than tamoxifen, and was more active in decreasing uterine weight of mature rats and 17 beta-estradiol-treated immature rats. "
|2.||Estrogen Receptor Modulators (Antiestrogen)
|1.||Drug Therapy (Chemotherapy)